📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Cyient DLM Shareholders Approve Variation in IPO Proceeds Utilization with 99.99% Majority
Cyient DLM shareholders have passed a special resolution to vary the objects and terms of utilization of the company's Initial Public Offering (IPO) proceeds. The resolution also includes an extension of the time limit for utilizing these funds, providing the company with greater operational flexibility. The proposal received overwhelming support, with 99.99% of the total votes cast in favor. This approval allows the management to reallocate capital or adjust timelines based on current business requirements and market conditions.
Key Highlights
Special resolution passed to vary IPO objects and extend the utilization timeline for proceeds.
The resolution received 99.9967% approval, with 63,704,092 votes in favor and only 2,104 against.
100% of the promoter group (41,366,502 votes) and 100% of public institutions (22,290,857 votes) supported the move.
The voting process was conducted via remote e-voting from February 7 to March 8, 2026.
A total of 63.7 million valid votes were cast out of a shareholder base of 104,162.
💼 Action for Investors
Investors should monitor the company's future disclosures to understand the specific changes in how the IPO funds will now be deployed. The near-unanimous institutional support suggests confidence in the management's revised capital allocation strategy.
Cyient DLM to reallocate ₹36.85 crore of IPO proceeds to working capital
Cyient DLM is seeking shareholder approval via a postal ballot to modify the utilization of its IPO proceeds. The company proposes to reallocate ₹36.85 crore originally earmarked for Capital Expenditure to meet incremental Working Capital requirements. Additionally, the timeline for the utilization of these funds has been extended to Fiscal Year 2026-27. This move indicates a strategic shift toward prioritizing operational liquidity over immediate fixed asset investments.
Key Highlights
Reallocation of ₹36.85 crore from Capital Expenditure to Working Capital requirements
Revised Working Capital allocation increased to ₹327.94 crore from the original ₹291.09 crore
Capital Expenditure budget significantly reduced to ₹6.72 crore following the transfer
Utilization timeline for remaining IPO proceeds extended through Fiscal Year 2026-27
General Corporate Purposes budget increased by ₹4.20 crore due to lower-than-expected IPO issue expenses
💼 Action for Investors
Investors should evaluate whether the shift toward working capital reflects higher inventory requirements or slower-than-expected execution of capital projects. Monitor the upcoming voting results and management's commentary on the revised growth timeline.
Cyient DLM Q3 FY26: Strong Order Intake of ₹387 Cr and 1.3 Book-to-Bill Ratio
Cyient DLM reported a robust order intake of ₹387 crores in Q3 FY26, achieving a book-to-bill ratio of 1.3 for the quarter and 1.56 YTD. While revenue was soft due to holiday-related push-outs and tariff uncertainties, management expects these shipments to recover in Q4. The company maintained double-digit EBITDA margins, though results were impacted by one-time labor code adjustments and aborted M&A-related expenses. Strategic focus remains on high-margin Build-to-Spec (B2S) programs and expansion into European and defense markets.
Key Highlights
Reported a healthy order intake of ₹387 crores with a book-to-bill ratio of 1.3 for the quarter.
Year-to-date (YTD) book-to-bill ratio stands strong at 1.56, providing high revenue visibility for coming quarters.
Added 2 new strategic logos in the medical and industrial sectors and commenced revenue from B2S programs.
EBITDA margins were impacted by one-time costs related to a new labor code and expenses from a non-materialized M&A deal.
Management noted revenue softness was temporary, driven by customer wait-and-watch modes regarding global tariff uncertainties.
💼 Action for Investors
Investors should monitor the execution of the ₹387 crore order book in Q4 to confirm that the Q3 revenue softness was indeed temporary. The increasing mix of Build-to-Spec (B2S) and defense contracts suggests long-term margin expansion potential.
Cyient DLM Q3 FY26: Revenue Drops 31.7% YoY to ₹3,033 Mn; EBITDA Margins Expand to 10.2%
Cyient DLM reported a 31.7% YoY decline in revenue to ₹3,033 million for Q3 FY26, primarily due to the completion of a large defense order in the previous fiscal year. Despite the revenue contraction, normalized EBITDA margins improved significantly by 207 bps to 10.2%, demonstrating operational resilience and a better product mix. The order backlog remains robust at ₹23,494 million, bolstered by a strong quarterly order intake of ₹3,871 million. The company is actively diversifying its portfolio, adding new logos in the Medical and Industrial sectors and increasing its Box Build revenue share to 31%.
Key Highlights
Revenue decreased 31.7% YoY to ₹3,033 Mn due to a high base effect from a large order completion in FY25.
Normalized EBITDA margin expanded by 207 bps YoY to 10.2%, reflecting improved efficiency and revenue quality.
Order backlog stands at a healthy ₹23,494 Mn with a strong quarterly intake of ₹3,871 Mn.
Box Build share of revenue increased to 31% compared to 23% in Q3 FY25, indicating a shift towards higher value-add services.
Defense segment saw an 86% YoY degrowth, while the Aerospace segment grew by 13% YoY.
💼 Action for Investors
Investors should focus on the company's ability to execute its strong ₹23.5 billion order book and the growth in the Aerospace and Med-Tech segments to compensate for the volatile Defense revenue. The expansion in EBITDA margins despite lower revenue is a positive indicator of underlying operational strength.
Cyient DLM Q3 FY26: Revenue Drops 31.7% YoY, Normalized PAT Rises to INR 13.84 Cr
Cyient DLM reported a significant revenue decline of 31.7% YoY to INR 303.3 crores in Q3 FY26, primarily due to customer-side slowdowns and temporary one-off items. Despite the top-line pressure, normalized EBITDA margins improved by 207bps to 10.2%, and normalized PAT rose to INR 13.84 crores. A key positive is the strong YTD order intake of over INR 1,400 crores, representing an 87% YoY growth, which suggests a robust recovery pipeline. The company also maintained positive YTD Free Cash Flow of INR 754 million.
Key Highlights
Revenue for Q3 FY26 stood at INR 303.3 crores, a decrease of 31.7% YoY.
Normalized EBITDA margin expanded by 207bps YoY to 10.2%, reaching INR 30.94 crores.
YTD order intake surged 87% YoY to over INR 1,400 crores, with INR 387 crores secured in Q3.
Normalized PAT for the quarter was INR 13.84 crores (4.6% margin), while reported PAT was INR 11.2 crores.
Year-to-date Free Cash Flow remains healthy at INR 754 million.
💼 Action for Investors
Investors should focus on the strong order book growth and margin expansion as indicators of long-term health, while monitoring if the Q4 volume ramp-ups materialize to offset the current revenue decline. The stock may experience volatility due to the sharp YoY revenue drop, but the operational resilience and new program wins provide a defensive cushion.
Cyient DLM Q3 FY26: Revenue Drops 31.7% YoY, Normalized EBITDA Margins Expand to 10.2%
Cyient DLM reported a challenging Q3 FY26 with revenue declining 31.7% YoY to ₹3,033 million, primarily due to the completion of a large defense order in the previous fiscal year. However, the company demonstrated operational resilience as normalized EBITDA margins expanded by 207 bps to 10.2%, driven by a better product mix and cost management. The order backlog remains strong at ₹23,494 million, bolstered by a robust quarterly order intake of ₹3,871 million. The company is successfully pivoting towards higher-value segments, with Box Build share increasing to 31% of revenue.
Key Highlights
Revenue decreased 31.7% YoY to ₹3,033 million due to high base effect from large order completion in FY25.
Normalized EBITDA margin improved by 207 bps YoY to 10.2%, reflecting improved operational efficiency and revenue quality.
Order backlog reached ₹23,494 million with a strong quarterly order intake of ₹3,871 million.
Box Build revenue share increased significantly to 31% compared to 21% in the same quarter last year.
Reported PAT stood at ₹112 million, while normalized PAT (excluding M&A and wage code one-offs) was ₹138 million.
💼 Action for Investors
Investors should focus on the robust order book and margin expansion as indicators of long-term health despite the temporary revenue dip. Monitor the company's ability to convert the ₹23,494 million backlog into revenue in the upcoming quarters.
Cyient DLM Q3 FY26 PAT at ₹112.3M; Revenue Declines 31.7% YoY to ₹3,033M
Cyient DLM reported a consolidated revenue of ₹3,033.47 million for Q3 FY26, marking a significant 31.7% decline compared to ₹4,442.36 million in the same quarter last year. While Net Profit remained relatively flat YoY at ₹112.33 million, it witnessed a sharp sequential drop from ₹321.45 million in Q2 FY26. The company is seeking shareholder approval to vary the objects of its IPO funds, of which ₹451.27 million remains unutilised. Additionally, the company recognized a ₹16 million expense due to the implementation of new national labour codes.
Key Highlights
Consolidated revenue for Q3 FY26 fell to ₹3,033.47 million from ₹4,442.36 million YoY.
Net profit for the quarter stood at ₹112.33 million, a marginal increase from ₹109.91 million YoY but down 65% QoQ.
Unutilised IPO proceeds as of December 31, 2025, stand at ₹451.27 million, with a proposal to vary fund objects.
Recognized a one-time provision of ₹16 million for defined benefit obligations following new Government labour codes.
9M FY26 consolidated revenue reached ₹8,924.08 million with a total net profit of ₹508.41 million.
💼 Action for Investors
Investors should exercise caution due to the significant YoY revenue contraction and the sharp sequential decline in profitability. Monitor the upcoming shareholder vote regarding the change in IPO fund utilization for clues on the company's revised capital allocation strategy.
Cyient DLM Shareholders Approve Appointment of Four Independent Directors with High Majority
Cyient DLM Limited has successfully passed four special resolutions via postal ballot for the appointment and re-appointment of Independent Directors. Dr. Ganesh Natarajan and Mr. Giridhar Aramane were appointed as new Independent Directors, receiving 98.72% and 99.99% support respectively. Dr. Vanitha Datla and Mr. Jehangir Ardeshir were re-appointed for second terms, both securing approximately 89.6% of the votes. The high voter turnout of nearly 80% reflects strong institutional and promoter engagement in the company's governance.
Key Highlights
Appointment of Mr. Giridhar Aramane received near-unanimous approval with 99.99% votes in favor
Dr. Ganesh Natarajan's appointment as Independent Director approved with 98.72% majority
Re-appointments of Dr. Vanitha Datla and Mr. Jehangir Ardeshir passed with 89.60% and 89.61% support
Total voting turnout reached 79.90% of outstanding shares, involving 63.4 million votes
All resolutions were passed as Special Resolutions through a remote e-voting process ending January 11, 2026
💼 Action for Investors
Investors should take confidence in the company's strengthened board and high level of shareholder participation. No immediate portfolio changes are required as these are positive governance-related developments.